TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023

HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy.

Helena A Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.